UK Markets closed

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
31.08+0.65 (+2.14%)
At close: 04:00PM EDT
31.08 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close30.43
Open30.87
Bid27.00 x 900
Ask33.95 x 1000
Day's range30.48 - 31.11
52-week range27.42 - 49.07
Volume520,992
Avg. volume671,808
Market cap20.44B
Beta (5Y monthly)0.75
PE ratio (TTM)47.01
EPS (TTM)0.66
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est46.36
  • Globe Newswire

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement COPENHAGEN, Denmark; May 17, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 19,302 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 450 shares at DKK 623.50,2,500 shares at DKK 636.50,2,800 shares at DKK 939.50,6,837 shares at DKK 1,025.00,773 sha

  • Business Wire

    Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

    COPENHAGEN, Denmark, May 12, 2022--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, will be presented at the European Hematology Association (EHA) Annual Congress, being held in Vienna, Austria, and virtually, June 9-12. The presentations will include data from various clinical trials, including multiple arms of the phase 1b/2 EPCORE™ NHL-2 trial, evaluating the safety and preliminary

  • Globe Newswire

    Genmab Announces Financial Results for the First Quarter of 2022

    May 11, 2022 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022 Highlights DARZALEX® net sales as reported by Johnson & Johnson increased 36% compared to the first three months of 2021 to USD 1,856 million, resulting in royalty revenue of DKK 1,501 millionGenmab updates its 2022 financial guidance “During the first quarter of 2022, there were continued advancements in our pipeline, including the first patient dosed with DuoBody®-CD3xB7H4 (GEN1047), the presentation of